C1orf210

Across TCGA pan-cancer cohorts, C1orf210 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of C1orf210’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where C1orf210 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types C1orf210 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and COAD are the cancer types where C1orf210 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in C1orf210 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	−1.737	<.001	12	view →
HNSC	Male	All	−0.673	<.001	6	view →
COAD	All	All	−0.644	.005	6	view →
LSCC	Male	II,III,IV	−0.547	<.001	5	view →
PDAC	All	All	−0.504	.006	2	view →
LUAD	All	All	+0.144	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

C1orf210–CCRCC

Open the CCRCC breakdown →